How many insider trades does FilingIQ track for NSRX?

FilingIQ tracks 3 Form 4 insider transactions for NSRX (Nasus Pharma Ltd), covering filings from Mar 31, 2026 onwards. 3 of those were filed in the last 90 days.

Are NSRX insiders net buyers or net sellers?

Across the full Form 4 history for NSRX, 3 transactions (100%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does NSRX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is NSRX in?

Nasus Pharma Ltd (NSRX) is classified in the Healthcare sector, specifically Drug Manufacturers - General, with a current market capitalisation of $26.00M.

NSRX insider trading

NYSE American Healthcare

Nasus Pharma Ltd — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

100% / 0%

Market cap

$26.00M

About Nasus Pharma Ltd

Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.

Company website: www.nasuspharma.com

NSRX insider activity at a glance

FilingIQ has scored 3 insider transactions for NSRX since Mar 31, 2026. The most recent filing in our index is dated Jun 17, 2026.

Across the full history, 3 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on NSRX insider trades is 65.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live NSRX trades on FilingIQ Raw filings on SEC EDGAR

Latest NSRX Form 4 filings

Teleman Dan Benjamin Chief Executive Officer

P Mar 31, 2026

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,196

UNITED THERAPEUTICS Corp

APLS 275

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

GH 191

Guardant Health, Inc.

First Tracks Biotherapeutics, Inc.

NTRA 133

Natera, Inc.

Frequently asked

How many insider trades does FilingIQ track for NSRX?: FilingIQ tracks 3 Form 4 insider transactions for NSRX (Nasus Pharma Ltd), covering filings from Mar 31, 2026 onwards. 3 of those were filed in the last 90 days.
Are NSRX insiders net buyers or net sellers?: Across the full Form 4 history for NSRX, 3 transactions (100%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does NSRX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is NSRX in?: Nasus Pharma Ltd (NSRX) is classified in the Healthcare sector, specifically Drug Manufacturers - General, with a current market capitalisation of $26.00M.

Methodology & sources

Every NSRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.